Assertion: actinium | /r/CapableOf | target antigen
Facets:
value: for targeted conditioning
type: PURPOSE
Source sentences:
text: Apart from Iomab-B, Actinium is developing a multi-disease, multi-target pipeline of clinical-stage ARCs, targeting the antigens CD45 and CD33, for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies, including Acute Myeloid Leukemi(AML)